Matt Liu

Matt Liu, PhD, DABT, MBA, is a Vice President of Toxicology at Schrödinger, where they oversee preclinical safety evaluation and manage late-stage research assets. With a doctorate in Pharmacology & Toxicology and an MBA, Matt has a comprehensive understanding of the nonclinical drug development process, supporting global regulatory submissions. Their previous roles include Principal Scientist at Merck Research Laboratories, Director of Toxicology at Regeneron, and Associate Principal Scientist at Schering-Plough Research Institute. Matt has contributed to the development of small molecules, monoclonal antibodies, and therapies for various therapeutic areas, including oncology and immunology.